Michael A. Matter

Michael A. Matter

Auto-generated profile, based on publicly available information

Michael A. Matter

Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zurich , University of Zurich, Zurich

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MMMichael A Matter
Michael A Matter
Francesco PaneniFrancesco Paneni
Francesco Paneni
PLPeter Libby
Peter Libby
SFStefan Frantz
Stefan Frantz
BSBarbara Stähli
Barbara Stähli
CMChristian M Matter
Christian M Matter
Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare ‘The Good’ (repair and defence) while treating ‘The Bad’ (smouldering RIR) and capturing ‘The Ugly’ (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.

28 December 2024 in Medical Image Analysis
Verified
Journal Article
Open access
FLFabian Laumer
Fabian Laumer
LRLena Rubi
Lena Rubi
MMMichael A. Matter
Michael A. Matter
SBStefano Buoso
Stefano Buoso
GFGabriel Fringeli
Gabriel Fringeli
CMChristian M Matter
Christian M Matter
Transthoracic Echocardiography (TTE) is a crucial tool for assessing cardiac morphology and function quickly and non-invasively without ionising radiation. However, the examination is subject to intra- and inter-user variability and recordings are often limited to 2D imaging and assessments of end-diastolic and end-systolic volumes. We have developed a novel, fully automated machine learning-based framework to generate a personalised 4D (3D plus time) model of the left ventricular (LV) blood pool with high temporal resolution. A 4D shape is reconstructed from specific 2D echocardiographic views employing deep neural networks, pretrained on a synthetic dataset, and fine-tuned in a self-supervised manner using a novel optimisation method for cross-sectional imaging data. No 3D ground truth is needed for model training. The generated digital twins enhance the interpretation of TTE data by providing a versatile tool for automated analysis of LV volume changes, localisation of infarct areas, and identification of new and clinically relevant biomarkers. Experiments are performed on a multicentre dataset that includes TTE exams of 144 patients with normal TTE and 314 patients with acute myocardial infarction (AMI). The novel biomarkers show a high predictive value for survival (area under the curve (AUC) of 0.82 for 1-year all-cause mortality), demonstrating that personalised 3D shape modelling has the potential to improve diagnostic accuracy and risk assessment.

23 September 2025 in Cardiovascular Research
Verified
Journal Article
Open access
YWYu-Jen Wang
Yu-Jen Wang
MMMichael A Matter
Michael A Matter
CMChristian M Matter
Christian M Matter

25 December 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MMMichael A. Matter
Michael A. Matter
ACAlessandro Candreva
Alessandro Candreva
BSBarbara E. Stähli
Barbara E. Stähli
DHDik Heg
Dik Heg
RKRoland Klingenberg
Roland Klingenberg
CTChristian Templin
Christian Templin

21 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
FLFabian Laumer
Fabian Laumer
LRLena Rubi
Lena Rubi
MMMichael Matter
Michael Matter
SBStefano Buoso
Stefano Buoso
GFGabriel Fringeli
Gabriel Fringeli
CMChristian M Matter
Christian M Matter
Transthoracic Echocardiography (TTE) is a crucial tool for assessing cardiac morphology and function quickly and non-invasively without ionizing radiation. However, the examination is subject to intra- and inter-user variability and recordings are often limited to 2D imaging and assessments of end-diastolic and end-systolic volumes. Current 3D TTE is time-consuming and provides lower image quality than 2D TTE. We have developed a novel, fully automated machine learning-based framework to generate a 4D (3D plus time) personalized model of the left ventricular (LV) blood pool. This digital twin was generated from specific 2D echocardiographic views employing deep neural networks, pre-trained on a synthetic dataset, and fine-tuned in a self-supervised manner using a novel optimization method for cross-sectional imaging data. This 4D model enabled detailed three dimensional analyses of LV systolic and diastolic function with high temporal resolution. Validation was performed on a multi-center dataset encompassing TTE exams of 144 patients with normal TTEs (controls) and 314 patients with acute myocardial infarction (AMI). LV volume measurements in controls derived from the digital twin showed a high correlation with the values from the clinical TTE reports (Pearson correlation coefficient of 0.7). In AMI patients, these novel biomarkers showed a high predictive value for survival (area under the curve (AUC) of 0.82 for 1-year all-cause mortality) and and excellent diagnostic value for infarct localisation and quantification, bearing the potential to improve diagnostic accuracy and risk assessment. Thus, our digital twin allows for fully automated robust LV shape analyses over time including contractility, relaxation, and regional wall motion abnormalities aiming at replacing expensive 3D imaging modalities with cheaper and more versatile 2D cardiac ultrasound.